RxDoctor Payments Data

Kevin Kett, MD

Cardiovascular Disease · Waterbury, CTNPI 1669417184

Payments from drug & device makers

$1,973in general payments, 2019–2025

Across 51 payments — averaging $38.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$636
  • Amgen$332
  • Johnson & Johnson$199
  • E.r. Squibb & Sons, L.L.C.$180
  • Edwards Lifesciences$125
  • Pfizer$121
  • plus $381 from 9 others

What the payments were for

  • Food & beverage$1,966100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,973 in reported general payments places this provider in the 55th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$288,853
Medicare patients
1,471
Services billed
4,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban377$458,303
XareltoRivaroxaban365$453,112
Repatha SureclickEvolocumab92$103,964
EntrestoSacubitril/Valsartan57$72,710
FarxigaDapagliflozin Propanediol24$29,854
JardianceEmpagliflozin23$28,427
Praluent PenAlirocumab14$17,698
Metoprolol Succinate1,143$16,139
Rosuvastatin Calcium914$10,152
Spironolactone420$4,164
Digoxin80$3,919
Atorvastatin Calcium330$3,539
Losartan Potassium393$3,464
Amlodipine Besylate462$3,359
Amiodarone Hcl225$3,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$458,303377 claims
Johnson & JohnsonXarelto$199$453,112365 claims
NovartisEntresto$40$72,71057 claims
AstraZenecaFarxiga$11$29,85424 claims
Boehringer IngelheimJardiance$636$28,42723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →